AIM
HRTX icon

Aigen Investment Management’s Heron Therapeutics HRTX Stock Holding History

Aigen Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,717
Closed -$16.5K – 643
2025
Q4 		$16.5K Buy
+12,717
New +$15.7K ﹤0.01% 550
2024
Q3 		– Sell
-13,484
Closed -$47.2K – 848
2024
Q2 		$47.2K Buy
+13,484
New +$41.4K 0.01% 728
2022
Q1 		– Sell
-19,818
Closed -$179K – 785
2021
Q4 		$179K Buy
+19,818
New +$202K 0.01% 948
2020
Q1 		– Sell
-37,509
Closed -$881K – 1392
2019
Q4 		$881K Buy
+37,509
New +$830K 0.15% 208

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Aigen Investment Management's HRTX Position: Q1 2026 in Review

Aigen Investment Management sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 12,717 shares — an estimated $16.5K sold.

Aigen Investment Management first reported a position in HRTX in Q4 2019 and held it in 4 quarters. The position peaked at $881K in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Aigen Investment Management reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 12,717 Heron Therapeutics shares in Q1 2026, an estimated $16.5K.
  • Aigen Investment Management first reported a position in Heron Therapeutics in Q4 2019 and held it in 4 quarters.
  • Aigen Investment Management's Heron Therapeutics position peaked at $881K in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.